06 Oct 2026, 08:47 IST
Divi's Laboratories Limited
Motilal Oswal Financial Services Ltd. (MOFSL) · BUY · target ₹10,800
The velocity idea says oral Wegovy could raise peptide API needs ~73x per patient and that Proclamation 11020 gives India a 0% tariff rate on specialty drug classes, with a 21% earnings CAGR expected over FY26-28; CMP ₹9,540, SL ₹8,870.
From MOStMarketOutlook06102026, written by Motilal Oswal Financial Services Ltd. (MOFSL) and hosted by Investment Guru India. Orivam summarised it; the view is Motilal Oswal Financial Services Ltd. (MOFSL)'s, not Orivam's.
Open the original PDF on Investment Guru India →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.